ArticleHospital pharmacy2026
Risk Factors Associated with Thrombus Development Following Pharmacologic Anticoagulation Reversal with Coagulation Factor Xa [Recombinant], Inactivated-zhzo.
Article in Hospital pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Andexanet alfa (AA), a recombinant coagulation factor Xa, is approved as an antidote for the treatment of bleeding secondary to rivaroxaban and apixaban. While thromboembolism may serve as a risk with reversal of therapeutic anticoagulation, several landmark trials demonstrate higher rates with AA versus usual care. Objective: The purpose of this study was to identify independent patient-specific and hospital-associated risk factors corresponding to the development of thrombus in patients who have received AA. Methods: This was a retrospective cohort study conducted across six institutions comprised of academic and community settings. Patients aged 18 years and older who received AA from November 1, 2021 through June 30, 2024 during an inpatient hospitalization were included. The primary outcome evaluated the presence of select risk factors on thrombus development within 45 days of AA administration. Results: One hundred thirty-eight patients met inclusion criteria. Identification of thrombus occurred in 19/138 (13.8%) after receiving AA. Of the risk factors evaluated, a multivariate analysis demonstrated major surgery within 30 days of reversal (OR 3.72, 95% CI: 1.14-12.08, Conclusion: A strong association existed between major surgery within 30 days and thrombotic complications following AA administration. Larger studies are needed to validate these findings and refine risk stratification post-AA administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.